Enhancing the user experience with new capabilities and even more scientific content

Since the Drug Interaction Database (DIDB) was acquired by Certara in June 2023, we’ve been plotting a course for the future and making investments in technology and scientific expertise to deliver the best possible user experience and most value for users of the industry’s largest scientist-curated database to assess drug interactions and safety.

See a demonstration of the newest DIDB capability, a drug-drug interaction (DDI) calculator that allows you to explore the clinical DDI risk of a compound as a precipitant (or perpetrator) based on a drug’s properties and early in vitro results.

You’ll also hear a series of updates from DIDB leaders Isabelle Ragueneau-Majilessi and Jingjing Yu on the breadth of scientific content that’s being added to the platform, consulting services now available to help users get the most out of their DIDB license, and the recent launch of Certara’s Center of Excellence (CoE) in Drug Interaction Science.

演讲嘉宾

Isabelle Ragueneau-Majlessi, MD, MS
Distinguished Scientist, Drug Interaction Solutions, Certara

Dr. Ragueneau 是华盛顿大学的荣誉临床教授，25 年前，她与他人共同创建了药物相互作用数据库 (DIDB)。在 Certara，她是药物相互作用解决方案项目的负责人，并领导药物相互作用科学卓越中心。她是一名临床药理学家，在评估药物相互作用机制和临床意义方面具有深厚的专业知识。2022 年，她因在药物相互作用数据库方面所做的大量工作以及该工具对药物相互作用研究的影响，获得了美国药物滥用和不良反应学会颁发的 Gary Neil 药物开发创新奖。

Jingjing Yu, MD, PhD
Director, Drug Interaction Solutions, Certara

在收购华盛顿大学药物相互作用解决方案项目后，Dr. Yu 于 2023 年加入 Certara。她在药物代谢和临床药理学领域拥有超过 15 年的经验，通过在学术界和工业界的工作，她在药物相互作用领域积累了独特的专业知识。在 Certara，Dr. Yu 是药物相互作用解决方案总监，也是药物相互作用科学卓越中心的核心成员。她还是华盛顿州西雅图华盛顿大学制药系的副教授。